TG Therapeutics, Inc. (NASDAQ: TGTX) is a Healthcare company (Biotechnology) with a market capitalization of $9.5B. The Maz Rating grades it against the other companies in its sector.
TG Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $62.76, TG Therapeutics, Inc. trades at 84.3x trailing earnings, 10.6x sales and 15.4x book value, with an EV/EBITDA of 51.3. Over the last twelve months it generated about $898M of revenue and $113M of net income. It runs a gross margin of 82.7%, an operating margin of 21.5% and a net margin of 11.8%. It shows return on equity of 17.6%, return on invested capital of 10.3% and a free cash flow yield of 0.9%. On the balance sheet: a debt-to-equity ratio of 1.32 and a current ratio of 4.50. Over the past 52 weeks the share price ranged from $26.76 to $68.03, with a beta of 1.81.
TG Therapeutics, Inc. does not currently pay a dividend.
13 Wall Street analyst ratings cover the stock: 11 Buy, 1 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.